In conducting subgroup analyses for precise treatment selection for specific populations, the characteristics of patients who benefited from longer OS with combination therapy included: male gender, age<59, CP score of B7, tumors exceeding the up-to-7 criteria, tumor count of ≤2, tumor diameter >5 cm, and AFP ≥400 ng/ml. This evidence concerns the gene AFP and neoplasm.